Market closedNon-fractional
Alnylam Pharmaceuticals/ALNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Ticker
ALNY
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
2,100
Website
www.alnylam.com
ALNY Metrics
BasicAdvanced
$30B
Market cap
-
P/E ratio
-$2.65
EPS
0.41
Beta
-
Dividend rate
Price and volume
Market cap
$30B
Beta
0.41
Financial strength
Current ratio
3.174
Quick ratio
2.859
Long term debt to equity
-1,184.124
Total debt to equity
-1,224.187
Interest coverage (TTM)
-1.38%
Management effectiveness
Return on assets (TTM)
-3.05%
Return on equity (TTM)
138.80%
Valuation
Price to revenue (TTM)
14.892
Price to book
-137.73
Price to tangible book (TTM)
-137.73
Price to free cash flow (TTM)
233.395
Growth
Revenue change (TTM)
75.20%
Earnings per share change (TTM)
-69.51%
3-year revenue growth (CAGR)
51.96%
3-year earnings per share growth (CAGR)
-29.48%
What the Analysts think about ALNY
Analyst Ratings
Majority rating from 29 analysts.
ALNY Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$494M
12.42%
Net income
-$66M
-52.18%
Profit margin
-13.33%
-57.45%
ALNY Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.21
$1.15
-$1.10
-$0.52
-
Expected
-$1.37
-$1.34
-$1.32
-$1.18
-$1.11
Surprise
61.47%
-186.09%
-16.84%
-56.04%
-
ALNY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alnylam Pharmaceuticals stock?
Alnylam Pharmaceuticals (ALNY) has a market cap of $30B as of July 27, 2024.
What is the P/E ratio for Alnylam Pharmaceuticals stock?
The price to earnings (P/E) ratio for Alnylam Pharmaceuticals (ALNY) stock is 0 as of July 27, 2024.
Does Alnylam Pharmaceuticals stock pay dividends?
No, Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Alnylam Pharmaceuticals dividend payment date?
Alnylam Pharmaceuticals (ALNY) stock does not pay dividends to its shareholders.
What is the beta indicator for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals (ALNY) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Alnylam Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.